From The Editor

  1. AAV Manufacturing Field: An Interactive Look 3/17/2023

    Mapping the adeno-associated virus (AAV) therapeutic space gives us a glimpse into indication priorities for gene therapy, and a look at whose got their fingers in which partners’ pots. Check out this interactive graphic from DeciBio Principal Carl Schoellhammer, Ph.D. It's not only instructive, its kind of therapeutic to play with. 

  2. Cashing In On Biopharma Collaboration 3/14/2023

    How does a biopharma business that’s potentially years away from its first shot at therapeutic sales revenue thrive in a high-inflation, high-interest, supply-constrained business environment?

  3. What's In A “Biopharma” Name? 2/23/2023

    As exciting new modalities, hybrids, and conjugates blur therapeutic lines, let’s not forget what “bio” means, how biologic therapeutics are distinguished, and why they were delineated as such in the first place. Make sure you're not a BINO (Bio In Name Only) when you’re naming your “biotech.”

  4. FDA Submission Automation: Coming To A Cloud Near You 2/15/2023

    The FDA is laying the groundwork for standardized, cloud-based electronic submission standards via an initiative that leverages data automation and artificial intelligence. What will it mean to biopharma filers?

  5. Bench To Boardroom: A Scientist-Turned-CEO's Journey 2/13/2023

    Novadip Biosciences CEO Denis Dufrane, M.D., Ph.D. got a crash course in biopharma leadership, but not before he left cell therapy research on his own timeframe. He sat down with Bioprocess Online to tell us what he learned.

  6. Antibody-Drug Conjugates: Increasing Investment In R&D And Partnerhip 2/1/2023

    DeciBio’s Antibody-Drug Conjugates 2023 Industry Survey points to progress in ADC development. Respondents anticipate lower regulatory, financial, and R&D barriers as the technology matures. Senior Life Science Expert Joe Daccache, Ph.D. gave us an insider's look at the numbers.

  7. What's True Of Mice ≠ What's True Of Men 1/27/2023

    After losing his mother to pancreatic cancer, entrepreneur Alex Blyth launched an immuno-oncology company that’s developing a novel allogeneic cell therapy. The company, LIfT BioSciences, recently received a shot in the arm when it was accepted into Johnson & Johnson Innovation’s JLABS network.

  8. Can JP Morgan Help San Francisco? 1/25/2023

    My first in-person JP Morgan Healthcare Conference was great for business. It also left me wondering what the world's toniest healthcare conference is doing for the health of its ailing host city.

  9. A Personal Case For Drug Repurposing 1/20/2023

    Amidst the dealmaking and spectacle of the 41st Annual JP Morgan Healthcare Conference, a bright and personal light was cast on the value of a different kind of collaboration: drug repurposing. There’s a deep vein of patient benefit sitting on pharmacy shelves, and Michael Fajgenbaum, M.D. wants to tap it. 

  10. 60 Minutes To IND Success 1/6/2023

    On 1/24/23, Daniela Drago, Ph.D. and Kati Abraham will join us for the discussion, IND Success: Navigate Through The Regulatory Gray, and I hope you do, too. We’ll talk through reasons for clinical holds, offer tips for avoiding and addressing them, and share best practices on ensuring smooth submissions on your journey from development to the clinic.